Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of the Efficacy and Safety of Sirolimus, Everolimus or Mycophenolate in Renal Transplant Recipients Receiving Induction With Anti-thymocyte Globulin, Tacrolimus and Prednisone

Next Previous
Trial Profile

Comparison of the Efficacy and Safety of Sirolimus, Everolimus or Mycophenolate in Renal Transplant Recipients Receiving Induction With Anti-thymocyte Globulin, Tacrolimus and Prednisone

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Mycophenolate sodium (Primary) ; Sirolimus (Primary) ; Antithymocyte globulin; Prednisone; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Acronyms SEM

Most Recent Events

  • 23 Aug 2021 Status changed from active, no longer recruiting to completed.
  • 09 Jun 2021 Results (n=267) comparing the efficacy and safety of Sirolimus versus Everolimus versus Mycophenolate in kidney transplant recipients, presented at the 2021 American Transplant Congress
  • 08 Feb 2021 Planned End Date changed from 18 Jun 2021 to 18 Nov 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top